Product Overview

AOP Orphan's focus is on rare and special diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Intensive Care. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to rare and special diseases. 

Neurology & Metabolic Disorders

Adepend® Dependex®

Adepend is used as part of a comprehensive treatment programme against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.

Drug Facts
Active Ingredient
Naltrexone
HematoOncology

Anagrelide AOP

Drug Facts
Active Ingredient
Anagrelide
HematoOncology

BESREMi®

BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.

Drug Facts
Active Ingredient
Ropeginterferon alfa-2b
Intensive Care

Empressin ®

"Argipressin based vasopressor indicated for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory/resistant hypotension is present if the mean arterial blood pressure cannot be stabilized to >65 mmHg despite adequate volume substitution and application of catecholamines."

Drug Facts
Active Ingredient
Argipressin
Intensive Care

Empressin®

Drug Facts
Active Ingredient
Agripressin
Neurology & Metabolic Disorders

Naltrexone AOP

Drug Facts
Active Ingredient
Intensive Care

Nexodal

"Complete or partial reversal of CNS depressive effects, especially respiratory depression, caused by natural or synthetic opioids and partial agonist/antagonist opioids. It is also used to diagnose a suspected acute opioid overdose or intoxication or to reduce the effect of opioids, which were used for anesthesia in operations."

Drug Facts
Active Ingredient
Naloxone
Neurology & Metabolic Disorders

Ocaliva®

Drug Facts
Active Ingredient
Obeticholic acid
Intensive Care

Rapibloc ®

Landiolol hydrochloride is indicated for supraventricular tachycardia and for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. Landiolol hydrochloride is also indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. Landiolol is not intended for use in chronic settings.

Drug Facts
Active Ingredient
Landiolol
Cardiology & Pulmonology

Rapibloc®

Drug Facts
Active Ingredient
Cardiology & Pulmonology

Tadalalfil AOP

Tadalafil AOP is used to treat adults with pulmonary arterial hypertension (PAH) to improve exercise capacity (the ability to carry out physical activity).

Drug Facts
Active Ingredient
Neurology & Metabolic Disorders

Tetmodis®

Drug Facts
Active Ingredient
Tetrabenazine
Neurology & Metabolic Disorders

Wakix®

Drug Facts
Active Ingredient
Pitolisant